查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1974331

抗体-寡核苷酸复合物市场：按寡核苷酸类型、结合方法、标靶化策略、应用和最终用户划分－全球预测，2026-2030年

Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年抗体寡核苷酸复合物市场价值为 31.5 亿美元，预计到 2025 年将成长至 34.2 亿美元，复合年增长率为 8.89%，到 2030 年将达到 52.6 亿美元。

主要市场统计数据
基准年 2024 31.5亿美元
预计年份：2025年 34.2亿美元
预测年份：2030年 52.6亿美元
复合年增长率 (%) 8.89%

探索抗体-寡核苷酸复合物在精准医疗和诊断创新发展中的基础和重要性。

抗体-寡核苷酸偶联物代表了生物治疗创新领域的前沿，它结合了单株抗体的靶向特异性和核酸技术的精细调控能力。作为一种用途广泛的偶联物，它们能够将基因有效载荷精准地递送至特定细胞群，从而为标靶治疗和先进诊断开闢了新的前景。透过利用客製化的化学技术将寡核苷酸连接到抗体骨架上，研究人员正在克服传统的递送难题，提高组织穿透性并最大限度地减少脱靶效应。

从实验室到临床的整合方案：识别将重塑抗体寡核苷酸复合物开发的变革性技术转变。

结合化学和分子设计的创新彻底改变了抗体-寡核苷酸复合物的片段。位点特异性结合技术的最新进展消除了复合物的异质性，从而实现了可重复的药物动力学和可预测的体内分布。同时，具有可调节稳定性的新型连接子结构能够精确控制释放动力学，从而提高治疗指数并降低免疫抗原性。

2025年美国关税的累积影响评估：对供应链研究投资与跨境合作研究的影响

2025年，美国实施的新关税增加了抗体-寡核苷酸复合物生产供​​应链的复杂性。关键试剂（例如修饰寡核苷酸和特殊抗体）关税的提高导致投入成本上升。因此，研发预算被重新分配以应对这些额外成本，从而导致采购和供应商选择的策略性转变。

揭示寡核苷酸类型、结合方法、标靶策略、应用领域和最终用户等方面的关键细分见解。

清楚了解市场如何按关键参数细分，有助于获得可操作的洞察。基于寡核苷酸类型的检验揭示了明显的趋势。反义寡核苷酸持续展现出强大的标靶基因敲低能力，而siRNA-抗体复合物则利用RNA干扰通道达到瞬时基因静默。适体-抗体复合物因其双重辨识能力而脱颖而出，而胜肽核酸在治疗环境中则具有无与伦比的稳定性。

影响抗体寡核苷酸复合物的采用和成长模式的关键区域趋势分析：北美和南美、欧洲、中东、非洲和亚太地区。

区域趋势对抗体-寡核苷酸偶联物的开发和应用有着深远的影响。在美洲，成熟的生物製药中心和强大的创业融资系统持续加速早期研发和转化伙伴关係。此外，该地区的监管机构也积极与新型治疗方法框架合作，促进了高效的临床评估管道。

主要企业在抗体寡核苷酸复合物领域获得竞争优势的策略和创新亮点：全球参与企业概览

抗体-寡核苷酸偶联物领域的主要企业正透过专有平台技术和策略合作实现差异化竞争。创新生物技术公司正与学术机构建立合作关係，以儘早获得新型连接子化学和寡核苷酸修饰技术。同时，成熟的製药公司正利用其生产经验加速规模化生产，并将偶联物平台整合到更广泛的生物製药产品线中。

为指导产业领导者在抗体寡核苷酸偶联疗法领域进行创新优化和伙伴关係，提供切实可行的策略建议。

产业领导者应优先建构能够适应多种结合方法的灵活製造生态系统。投资模组化生产线可根据计划具体需求，在酵素法、化学法和亲和性和法之间无缝切换。此外，与原料供应商建立早期合作关係，可确保优先获得正在研发的新型寡核苷酸化学技术和抗体片段。

详细介绍了一套严谨的调查方法框架，整合了定性访谈、定量资料检验和多源三角测量程序。

本分析采用多方面方法，整合了定性和定量资料。初步调查包括对高级研发主管、製程开发科学家、法规事务专家以及积极参与复杂技术开发的关键意见领袖（KOL）进行结构化访谈。访谈通讯协定旨在捕捉他们对技术挑战、监管预期和策略投资重点的细緻见解。

从相关人员的观点来看，我们对影响抗体寡核苷酸复合物前景的策略需求和未来机会得出了一致的结论。

抗体特异性和寡核苷酸多功能性的融合正在为标靶治疗和精准诊断建立新的范式。偶联化学的进步、核酸疗法相关法规的明确性以及合作研究倡议的拓展，都在推动这一领域的成长。儘管地缘政治趋势和供应链挑战仍然存在，但积极的多元化发展和策略伙伴关係正在降低风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 抗体-寡核苷酸复合物市场：依寡核苷酸类型划分

  • 反义寡核苷酸
  • 适体抗体复合物
  • 胜肽核酸
  • siRNA-抗体复合物

第九章 抗体-寡核苷酸复合物市场：以结合方式划分

  • 基于亲和力-生物素亲和性
  • 直接化学键
  • 基于静电相互作用
  • 酶促结合

第十章 抗体-寡聚体复合物市场：标靶化策略

  • 细胞表面受体
  • 细胞内标靶
  • 病原体相关标靶

第十一章 抗体-寡核苷酸复合物市场：依应用划分

  • 诊断
  • 研究
  • 治疗
    • 自体免疫疾病
    • 循环系统疾病
    • 感染疾病
    • 神经系统疾病
    • 肿瘤学
    • 罕见疾病

第十二章 抗体寡核苷酸偶联物市场：依最终用户划分

  • 学术和研究机构
  • 製药和生物技术公司

第十三章 抗体-寡核苷酸复合物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗体寡聚体复合物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 抗体-寡聚体复合物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗体-寡核苷酸复合物市场

第十七章：中国抗体-寡核苷酸复合物市场

第十八章 竞争格局

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • AbbVie Inc.
  • Abzena Holdings (USA) LLC
  • Agilent Technologies Inc.
  • AstraZeneca PLC
  • Avidity Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • Eli Lilly and Company
  • GenScript BIoTech Corporation
  • Goodwin BIoTechnology Inc.
  • Ionis Pharmaceuticals, Inc.
  • Rockland Immunochemicals, Inc
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Tallac Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd
Product Code: MRR-4F7A6D4FD72D

The Antibody-oligonucleotide Conjugates Market was valued at USD 3.15 billion in 2024 and is projected to grow to USD 3.42 billion in 2025, with a CAGR of 8.89%, reaching USD 5.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.15 billion
Estimated Year [2025] USD 3.42 billion
Forecast Year [2030] USD 5.26 billion
CAGR (%) 8.89%

Exploring the Foundations and Significance of Antibody-Oligonucleotide Conjugates in Advancing Precision Medicine and Diagnostic Innovation

Antibody-oligonucleotide conjugates represent a frontier in biotherapeutic innovation, combining the target specificity of monoclonal antibodies with the regulatory finesse of nucleic acid technologies. Emerging as a versatile class of conjugates, they enable precise delivery of genetic payloads to defined cellular populations, opening new vistas in targeted therapy and advanced diagnostics. Leveraging bespoke chemistries that tether oligonucleotides to antibody scaffolds, researchers are overcoming historical delivery challenges to achieve enhanced tissue penetration and minimized off-target effects.

This convergence of two potent modalities is driven by a clear vision: harnessing molecular specificity to address complex disease mechanisms. In recent years, breakthroughs in linker design, site-specific conjugation, and oligonucleotide stabilization have coalesced to transform theoretical constructs into tangible clinical assets. Consequently, stakeholders across pharmaceutical, academic, and biotechnology sectors are channeling resources into refining these conjugates, anticipating both therapeutic breakthroughs and next-generation diagnostic tools.

Moreover, the alignment of regulatory guidelines with innovation pipelines has accelerated timelines for investigational new drug submissions. As a result, antibody-oligonucleotide research is transitioning from bench-scale proof-of-concept studies to early-phase clinical trials, signifying a pivotal shift in the paraphernalia of precision medicine. In this report, the foundational landscape is mapped out to guide strategic decisions and illuminate the opportunities inherent in this dynamic field.

Identifying the Transformative Technological Shifts Reshaping Antibody-Oligonucleotide Conjugate Development from Bench to Bedside Integration Scenarios

Innovation in conjugation chemistry and molecular design has catalyzed transformative shifts in the field of antibody-oligonucleotide conjugates. In recent years, advancements in site-specific attachment strategies have eliminated heterogeneous populations of conjugates, leading to reproducible pharmacokinetics and predictable biodistribution. Simultaneously, novel linker constructs with tunable stability profiles have empowered researchers to fine-tune release kinetics, thereby enhancing therapeutic indices and mitigating immunogenicity.

Beyond chemistry, integration of in silico modeling and high-throughput screening has optimized oligonucleotide sequences for both affinity and specificity, reducing development timelines and resource expenditure. As a result, platform technologies are emerging that enable plug-and-play assembly of antibody and oligonucleotide modules. Moreover, the maturation of regulatory frameworks for nucleic acid therapies has provided clearer pathways for preclinical validation, driving greater alignment between discovery teams and regulatory authorities.

Furthermore, increased collaboration between academic consortia and industrial research centers has fostered knowledge transfer, enabling rapid iteration on design principles and accelerating the transition from discovery to clinical proof of concept. These transformative shifts collectively signal a maturation of the antibody-oligonucleotide conjugate ecosystem, setting the stage for the next wave of targeted therapeutics and diagnostic solutions.

Evaluating the Cumulative Consequences of Imposed United States Tariffs for 2025 on Supply Chains Research Investments and Cross-Border Collaborations

In 2025, the implementation of new United States tariffs has introduced a layer of complexity to the supply chains supporting antibody-oligonucleotide conjugate manufacturing. Increased duties on critical reagents such as modified oligonucleotides and specialized antibodies are contributing to elevated input costs. Consequently, research budgets are being reallocated to buffer these additional expenses, leading to strategic shifts in sourcing and vendor selection.

Furthermore, the tariffs have incentivized onshoring of reagent production, prompting stakeholders to evaluate domestic partnerships and localized manufacturing capabilities. In addition, cross-border collaborations are being renegotiated to account for the financial impact of tariff differentials, particularly for organizations relying on integrated supply networks in Europe and Asia-Pacific. As a direct outcome, lead times for critical components are being reassessed, and contingency planning has become a central focus of project management discussions.

Despite these headwinds, some organizations are viewing this as an opportunity to strengthen supply resilience. By diversifying procurement channels and investing in strategic inventory buffers, companies are striving to maintain research momentum while mitigating cost exposure. In this context, the cumulative impact of these tariffs extends beyond immediate financial considerations to reshape strategic planning, risk management, and long-term partnership agreements across the antibody-oligonucleotide conjugate landscape.

Unveiling Critical Segmentation Insights Across Oligonucleotide Types Conjugation Methodologies Targeting Strategies Applications and End Users

A clear understanding of how the market divides across critical parameters offers actionable intelligence. When examining the system based on oligonucleotide type, distinct trends emerge: antisense oligonucleotides continue to demonstrate robust target knockdown potential, while siRNA-antibody conjugates leverage RNA interference pathways for transient gene silencing. Aptamer-antibody conjugates stand out for their dual recognition capabilities, and peptide nucleic acids bring unparalleled stability into the therapeutic milieu.

Conjugation methodology further stratifies the landscape. Enzymatic conjugation approaches provide unparalleled site specificity, whereas direct chemical linkages deliver streamlined scalability. Electrostatic interaction-based assemblies afford reversible attachment, and affinity-driven avidin-biotin systems offer modularity, each method tailored to particular development imperatives and manufacturing constraints.

Targeting strategy sheds additional light on application opportunities. Conjugates aimed at cell surface receptors enable precise tissue-specific delivery, whereas those designed for intracellular targets require careful navigation of membrane translocation barriers. Pathogen-associated target conjugates are carving a niche in infectious disease applications, highlighting the versatility of this class.

Application-centric segmentation underscores divergent end uses. Diagnostic implementations capitalize on high-affinity binding for biomarker detection, research applications exploit modular design for mechanistic studies, and therapeutic deployments span autoimmune disorders, cardiovascular diseases, infectious diseases, neurological disorders, oncology, and rare diseases. The plurality of therapeutic areas underscores the platform's adaptability.

Finally, end-user perspectives differentiate demand dynamics. Academic and research institutions prioritize foundational understanding and experimental flexibility, while pharmaceutical and biotechnology companies emphasize scalability, regulatory alignment, and commercialization potential.

Dissecting Key Regional Dynamics Influencing Antibody-Oligonucleotide Conjugate Adoption and Growth Patterns across Americas EMEA and Asia-Pacific

Regional dynamics exert a profound influence on the development and adoption of antibody-oligonucleotide conjugates. In the Americas, established biopharmaceutical hubs and robust venture funding ecosystems continue to accelerate early-stage research and translational partnerships. This region's regulatory bodies have also demonstrated proactive alignment with novel therapy frameworks, facilitating streamlined pathways to clinical evaluation.

Across Europe, the Middle East, and Africa, the emphasis on harmonized regulatory standards is fostering collaborative clinical networks and pan-regional consortia. Investment in precision medicine infrastructure has increased, particularly in consortium-led initiatives that seek to integrate cutting-edge conjugate platforms into national healthcare strategies. Moreover, emerging centers of excellence are positioning the region as both a research incubator and a manufacturing base for conjugate components.

In the Asia-Pacific region, economic growth and government-led biotechnology initiatives are catalyzing significant expansion in local manufacturing capacity. Cost-competitive production combined with scaling of contract research networks is attracting global partnerships. Additionally, patient populations with high unmet medical needs are driving localized clinical research, and favorable intellectual property regulations in certain jurisdictions are encouraging technology transfer and joint ventures.

Highlighting Leading Corporate Strategies and Innovations Driving Competitive Edge in the Antibody-Oligonucleotide Conjugate Domain Global Players Overview

Leading organizations in the antibody-oligonucleotide conjugate arena are differentiating through proprietary platform technologies and strategic alliances. Innovative biotechnology firms are forging collaborations with academic centers to gain early access to novel linker chemistries and oligonucleotide modifications. Conversely, established pharmaceutical companies are integrating conjugate platforms into broader biologics pipelines, leveraging in-house manufacturing expertise to expedite scale-up.

Partnerships between instrument providers and therapeutic developers are also on the rise, enabling seamless end-to-end workflows from conjugate synthesis to analytical validation. Strategic alliances are extending into contract research organization networks, granting developers access to specialized capabilities in cell-based assays, pharmacokinetic analysis, and toxicology studies tailored for conjugate modalities.

In parallel, certain niche technology firms are differentiating through advanced computational tools that predict conjugate stability and optimize sequence design. Their integration into drug discovery workflows is demonstrating potential for reducing development timelines and improving lead candidate selection. Together, these corporate strategies highlight a competitive landscape driven by collaborative models, platform scalability, and the pursuit of first-mover advantage in key therapeutic segments.

Delivering Actionable Strategic Recommendations to Guide Industry Leaders through Innovation Optimization and Collaborative Partnerships in Conjugate Therapeutics

Industry leaders should prioritize the establishment of flexible manufacturing ecosystems capable of accommodating diverse conjugation methodologies. By investing in modular production lines, organizations can switch seamlessly between enzymatic, chemical, and affinity-based approaches in response to project-specific requirements. Furthermore, forging early-stage collaborations with raw material suppliers will secure preferential access to novel oligonucleotide chemistries and antibody fragments under development.

In addition, companies should cultivate cross-functional teams that integrate computational modeling, analytical chemistry, and regulatory expertise. Such multidisciplinary units can drive rapid prototyping of conjugates, ensuring that design iterations are informed by both in silico predictions and empirical validation. Equally important is engaging proactively with regulatory authorities to define clear experimental endpoints and mitigate potential approval bottlenecks.

To address geopolitical and supply chain uncertainties, it is advisable to diversify procurement across regions and explore dual sourcing for critical reagents. Establishing strategic inventory buffers will safeguard research continuity, while localized partnerships can reduce tariff exposure and lead time variability. Finally, organizations should explore co-development agreements with clinical networks to accelerate translational studies in high-priority therapeutic areas, thereby aligning organizational capabilities with market needs and patient demands.

Detailing Rigorous Research Methodology Framework Incorporating Qualitative Interviews Quantitative Data Validation and Multisource Triangulation Procedures

This analysis is grounded in a multi-pronged methodology that synthesizes qualitative and quantitative inputs. Primary research involved structured interviews with senior R&D executives, process development scientists, regulatory affairs specialists, and key opinion leaders actively engaged in conjugate technology development. Interview protocols were designed to capture nuanced perspectives on technical challenges, regulatory expectations, and strategic investment priorities.

Complementing these insights, secondary research encompassed an exhaustive review of patent filings, regulatory guidance documents, peer-reviewed literature, and white papers from leading scientific organizations. A specialized database was constructed to track novel conjugation chemistries, linker innovations, and oligonucleotide modifications, ensuring that the report reflects the latest advancements in the field.

Data triangulation was employed to validate findings across sources, enabling the reconciliation of disparate insights and the identification of consistent trends. Comparative analysis of case studies and clinical trial registries provided real-world context for development progress and translational success. Together, these methodological layers underpin the credibility and robustness of the report's conclusions and strategic recommendations.

Drawing Consistent Conclusions on the Strategic Imperatives and Future Opportunities Shaping the Antibody-Oligonucleotide Conjugate Landscape with Stakeholder Perspectives

The convergence of antibody specificity and oligonucleotide versatility is establishing a new paradigm for targeted therapeutics and precision diagnostics. Growth is being propelled by advancements in conjugation chemistries, enhanced regulatory clarity for nucleic acid therapies, and an expanding base of collaborative research initiatives. While geopolitical dynamics and supply chain considerations present challenges, proactive diversification and strategic partnerships are mitigating risk.

Segment-specific insights reveal that siRNA-based conjugates and antisense modalities are driving early translational momentum, underpinned by robust targeting strategies and modular platform designs. Regional dynamics underscore the importance of localized manufacturing and regulatory harmonization, with the Americas leading in early-stage research, EMEA fostering collaborative clinical networks, and Asia-Pacific accelerating scale-up through government-backed initiatives.

Corporate landscapes are being defined by partnerships that bridge discovery platforms with manufacturing capabilities, and by computational tools that refine sequence design. Strategic recommendations for industry leaders coalesce around flexible production ecosystems, integrated multidisciplinary teams, and proactive engagement with regulatory bodies. Ultimately, antibody-oligonucleotide conjugates stand poised to transform the therapeutic and diagnostic landscape, offering a versatile toolkit to address unmet medical needs with unprecedented precision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibody-oligonucleotide Conjugates Market, by Oligonucleotide Type

  • 8.1. Antisense Oligonucleotide
  • 8.2. Aptamer-Antibody Conjugates
  • 8.3. Peptide Nucleic Acids
  • 8.4. siRNA-Antibody Conjugates

9. Antibody-oligonucleotide Conjugates Market, by Conjugation Methodology

  • 9.1. Avidin-biotin Affinity-based
  • 9.2. Direct Chemical Linkage
  • 9.3. Electrostatic Interaction-based
  • 9.4. Enzymatic Conjugation

10. Antibody-oligonucleotide Conjugates Market, by Targeting Strategy

  • 10.1. Cell Surface Receptors
  • 10.2. Intracellular Targets
  • 10.3. Pathogen-Associated Targets

11. Antibody-oligonucleotide Conjugates Market, by Application

  • 11.1. Diagnostics
  • 11.2. Research
  • 11.3. Therapeutics
    • 11.3.1. Autoimmune Disorders
    • 11.3.2. Cardiovascular Diseases
    • 11.3.3. Infectious Diseases
    • 11.3.4. Neurological Disorders
    • 11.3.5. Oncology
    • 11.3.6. Rare Diseases

12. Antibody-oligonucleotide Conjugates Market, by End-User

  • 12.1. Academic & Research Institutions
  • 12.2. Pharmaceutical & Biotechnology Companies

13. Antibody-oligonucleotide Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antibody-oligonucleotide Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antibody-oligonucleotide Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antibody-oligonucleotide Conjugates Market

17. China Antibody-oligonucleotide Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. AbbVie Inc.
  • 18.6. Abzena Holdings (US) LLC
  • 18.7. Agilent Technologies Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Avidity Biosciences, Inc.
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Danaher Corporation
  • 18.12. Eli Lilly and Company
  • 18.13. GenScript Biotech Corporation
  • 18.14. Goodwin Biotechnology Inc.
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Rockland Immunochemicals, Inc
  • 18.17. Sanofi SA
  • 18.18. Sarepta Therapeutics, Inc.
  • 18.19. Tallac Therapeutics, Inc.
  • 18.20. Thermo Fisher Scientific Inc.
  • 18.21. WuXi AppTec Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 13. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 121. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 136. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 143. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 145. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 157. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 164. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 171. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)